Cutaneous lupus induced by etanercept in rheumatoid arthritis;Lupus érythémateux cutané induit par étanercept au cours de la polyarthrite rhumatoïde

Revue de Medecine Interne

Volumn 29, Issue 9, 2008, Pages 744-747

  Abourazzak, F E ^a   Guggenbuhl, P ^b   Perdriger, A ^b   Meadeb, J ^b   Gando Cocley, N ^b   Chevrant Breton, J ^c   Hajjaj Hassouni, N ^a   Chales G ^b  

^a IBN SINA HOSPITAL   (Morocco)

^b SERVICE DE RHUMATOLOGIE   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Drug induced lupus; Etanercept; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; DNA; ETANERCEPT; HYDROXYCHLOROQUINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; FEMALE; HUMAN; IMMUNOFLUORESCENCE; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS;

ADULT; ANTIRHEUMATIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, CUTANEOUS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49849096625     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.06.003     Document Type: Article

References (27)

1. Garrison L., and McDonnell N. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 58 Suppl 1 (1999) 165-169
2. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomittent mehotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
3. Louis M., Rauch J., Armstrong M., and Fitzcharles M.-A. Induction of antibodies during prolonged treatment with infliximab. J Rheumatol 30 (2003) 2557-2562
4. De Bandt M., Vittecoq O., Descamps V., Le Loet X., and Meyer O. Anti-TNF alpha-induced systemic lupus erythematosus. Clin Rheumatol 22 (2003) 56-61
5. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
6. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48 (2003) 1015-1023
7. Morrow J.D., Schroeder H.A., and Perry H.M. Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects. Circulation 8 (1953) 829-839
8. Le Goff P., and Saraux A. Les lupus induits. Rev Rhum Ed Fr 66 (1999) 43-48
9. Yung R.L., and Richardson B.C. Drug-induced lupus. Rheum Dis Clin North Am 20 (1994) 61-86
10. Sibilia J. Les lupus induits par les médicaments. Rev Rhum Ed Fr 69 (2002) 355-369
11. e ed. (2000), Médecine-Sciences Flammarion, Paris 131-368 bis
12. Budinsky R.A., Roberts S.M., Coates E.A., Adams L., and Hess E.V. The formation of hydroxylamine by rat and human liver microsomes. Drug Metab Dispos 15 (1987) 37-43
13. Uetrecht J.P., Zahid N., and Rubin R.L. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem Res Toxicol 1 (1988) 74-78
14. Adams L.E., Balakrishnan K., Roberts S.M., Belcher R., Mongey A.B., Thomas T.J., et al. Genetic, immunologic and biotransformation studies of patients on procainamide. Lupus 2 (1993) 89-98
15. Bickerstaff M.C., Booto M., Hutchinson W.L., Herbert J., Teenant J.A., Bybee A., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5 (1999) 694-697
16. D'Auria F., Rovere-Querini P., Giazzon M., Ajello P., Baldissera E., Manfredi A., and Sabbadini M. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 255 (2004) 409-418
17. Palucka A.K., Blanck J.P., Bennett L., Pascual V., and Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci U S A. 102 (2005) 3372-3377
18. Sellam J., and Piette J.C. Les anti-TNF : une contre-indication ou un traitement prometteur du lupus ?. Rev Med Interne 27 (2006) 87-90
19. Physicians' desk reference, 55th ed. Montvale, NJ: Medical Economics company; 2001.
20. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., and De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52 (2005) 2192-2201
21. Allanore Y., Sellam J., Batteux F., Job Deslandre C., Weill B., and Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 22 (2004) 756-758
22. De Bandt M.J., Descamps V., and Meyer O. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis. Ann Rheum Dis 60 (2001) 175
23. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) 545-551
24. Crowson A.N., and Magro C.M. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 28 (1997) 67-73
25. Goodrich A.L., and Kohn S.R. Hydrochlorothiazide-induced lupus erythematosus: a new variant?. J Am Acad Dermatol 28 (1993) 1001-1002
26. Carter J.D., Valeriano-Marcet J., Kanik K.S., and Vasey F.B. Antinuclear antibody-negative, drug induced lupus caused by lisinopril. South Med J 94 (2001) 1122-1123
27. Jonsdottir T., Forslid J., Van Vollenhoven A., Harju A., Brannemark S., Klareskog L., and Van Vollenhoven R.F. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63 (2004) 1075-1078